ACR 257: Uterine Fibroids Awareness Month.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-08-30
This measure would proclaim the month of July 2018 as Uterine Fibroids Awareness Month in California and would recognize the need for greater research, treatment, and care options regarding uterine fibroids.
This measure would proclaim the month of July 2018 as Uterine Fibroids Awareness Month in California and would recognize the need for greater research, treatment, and care options regarding uterine fibroids.
This measure would proclaim the month of July 2018 as Uterine Fibroids Awareness Month in California and would recognize the need for greater research, treatment, and care options regarding uterine fibroids.
WHEREAS, Uterine fibroids are the most common noncancerous tumors that grow in the walls of the uterus (womb) in women of childbearing age, with no scientific confirmation of what causes the tumors; and
WHEREAS, Uterine fibroids may cause significant morbidity through their presence in the uterus and pelvic cavity. Symptoms of uterine fibroids include significant pelvic pain, abnormal uterine bleeding, reproductive dysfunction, miscarriages, early labor, and even infertility; and
WHEREAS, The pain, discomfort, stress, and other physical and emotional symptoms of living with uterine fibroids may significantly interfere with a womans quality of life, compromise her ability to function normally, work, or care for her family, and lead to more severe health and wellness issues; and
WHEREAS, Uterine fibroids are the most prevalent medical condition affecting women, with an estimated 30 percent of women developing a uterine fibroid by 35 years of age, and 80 percent of women developing a uterine fibroid by 50 years of age; and
WHEREAS, The exact number of affected women is unknown, as detection and diagnosis are difficult. Only one out of four women who have a uterine fibroid tumor exhibits symptoms severe enough to require treatment; and
WHEREAS, To properly diagnose uterine fibroids, access to health care is essential, as screening tests could include ultrasounds, magnetic resonance imaging, X-rays, and computerized tomography (CT) scans. Beyond diagnosis, surgery options include a myomectomy, which could potentially yield conception and full-term pregnancy complications, or a hysterectomy, which would make a woman unable to bear children. Invasive procedures like a myomectomy, however, are not recommended for women who want to conceive; and
WHEREAS, Fertility support, which is very common for women with uterine fibroids, is strongly contingent upon premium health care coverage. Lack of health care can strongly impact early detection, surgery options, and access to fertility support. Collectively, the side effects of uterine fibroids, invasive surgery options, and fertility issues considerably impact mental health and economic status due to missed work days and lost wages; and
WHEREAS, According to a study published in 2011, uterine fibroid tumors were estimated to cost the United States $5.9 billion to $34.4 billion annually with an estimated annual lost work cost of $1.6 billion to $17.2 billion through absenteeism and short-term disability in women between 25 and 54 years of age, inclusive; and
WHEREAS, The overall incidence of uterine fibroids is estimated to disproportionately and more severely impact African American and Hispanic women, resulting in an incidence rate that is three times greater in African American women and two times greater in Hispanic women compared to Caucasian women; and
WHEREAS, The differences in the incidence rates and the magnitude of the condition of uterine fibroids could be impacted by differences in access and use of health care services; and
WHEREAS, The State Department of Health Care Services and the State Department of Public Health, through a focus on womens health, encourage education and research on the condition to increase knowledge of uterine fibroids, improve methods of treatment, and develop an alternative to hysterectomies; and
WHEREAS, Observation of Uterine Fibroids Awareness Month in the month of July 2018 can assist in the aforementioned efforts, support and encourage women to engage in healthy dialogue, and promote a positive community; and
WHEREAS, Florida, Georgia, Maryland, New York, Pennsylvania, South Carolina, Virginia, Washington, D.C., and New Orleans, Louisiana, recognize Uterine Fibroids Awareness Month in July; and
WHEREAS, Public awareness and education campaigns on uterine fibroids prevention, screening, and symptoms are held during the month of July each year; and
WHEREAS, The San Diego Alumnae Chapter of Delta Sigma Theta Sorority, Inc., as part of its five-point programmatic thrust, conducted physical and mental health events in the City of San Diego, including a free Womens Health Forum on Uterine Fibroids. Its desire to expand awareness of the condition beyond the chapters region resulted in this statewide resolution; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby proclaims the month of July 2018 as Uterine Fibroids Awareness Month in California, recognizing the disparity in incidence rates among African American and Hispanic patients of uterine fibroids, and the need for greater research, treatment, and care options regarding uterine fibroids; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Uterine fibroids are the most common noncancerous tumors that grow in the walls of the uterus (womb) in women of childbearing age, with no scientific confirmation of what causes the tumors; and
WHEREAS, Uterine fibroids may cause significant morbidity through their presence in the uterus and pelvic cavity. Symptoms of uterine fibroids include significant pelvic pain, abnormal uterine bleeding, reproductive dysfunction, miscarriages, early labor, and even infertility; and
WHEREAS, The pain, discomfort, stress, and other physical and emotional symptoms of living with uterine fibroids may significantly interfere with a womans quality of life, compromise her ability to function normally, work, or care for her family, and lead to more severe health and wellness issues; and
WHEREAS, Uterine fibroids are the most prevalent medical condition affecting women, with an estimated 30 percent of women developing a uterine fibroid by 35 years of age, and 80 percent of women developing a uterine fibroid by 50 years of age; and
WHEREAS, The exact number of affected women is unknown, as detection and diagnosis are difficult. Only one out of four women who have a uterine fibroid tumor exhibits symptoms severe enough to require treatment; and
WHEREAS, To properly diagnose uterine fibroids, access to health care is essential, as screening tests could include ultrasounds, magnetic resonance imaging, X-rays, and computerized tomography (CT) scans. Beyond diagnosis, surgery options include a myomectomy, which could potentially yield conception and full-term pregnancy complications, or a hysterectomy, which would make a woman unable to bear children. Invasive procedures like a myomectomy, however, are not recommended for women who want to conceive; and
WHEREAS, Fertility support, which is very common for women with uterine fibroids, is strongly contingent upon premium health care coverage. Lack of health care can strongly impact early detection, surgery options, and access to fertility support. Collectively, the side effects of uterine fibroids, invasive surgery options, and fertility issues considerably impact mental health and economic status due to missed work days and lost wages; and
WHEREAS, According to a study published in 2011, uterine fibroid tumors were estimated to cost the United States $5.9 billion to $34.4 billion annually with an estimated annual lost work cost of $1.6 billion to $17.2 billion through absenteeism and short-term disability in women between 25 and 54 years of age, inclusive; and
WHEREAS, The overall incidence of uterine fibroids is estimated to disproportionately and more severely impact African American and Hispanic women, resulting in an incidence rate that is three times greater in African American women and two times greater in Hispanic women compared to Caucasian women; and
WHEREAS, The differences in the incidence rates and the magnitude of the condition of uterine fibroids could be impacted by differences in access and use of health care services; and
WHEREAS, The State Department of Health Care Services and the State Department of Public Health, through a focus on womens health, encourage education and research on the condition to increase knowledge of uterine fibroids, improve methods of treatment, and develop an alternative to hysterectomies; and
WHEREAS, Observation of Uterine Fibroids Awareness Month in the month of July 2018 can assist in the aforementioned efforts, support and encourage women to engage in healthy dialogue, and promote a positive community; and
WHEREAS, Florida, Georgia, Maryland, New York, Pennsylvania, South Carolina, Virginia, Washington, D.C., and New Orleans, Louisiana, recognize Uterine Fibroids Awareness Month in July; and
WHEREAS, Public awareness and education campaigns on uterine fibroids prevention, screening, and symptoms are held during the month of July each year; and
WHEREAS, The San Diego Alumnae Chapter of Delta Sigma Theta Sorority, Inc., as part of its five-point programmatic thrust, conducted physical and mental health events in the City of San Diego, including a free Womens Health Forum on Uterine Fibroids. Its desire to expand awareness of the condition beyond the chapters region resulted in this statewide resolution; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby proclaims the month of July 2018 as Uterine Fibroids Awareness Month in California, recognizing the disparity in incidence rates among African American and Hispanic patients of uterine fibroids, and the need for greater research, treatment, and care options regarding uterine fibroids; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Uterine fibroids are the most common noncancerous tumors that grow in the walls of the uterus (womb) in women of childbearing age, with no scientific confirmation of what causes the tumors; and
WHEREAS, Uterine fibroids may cause significant morbidity through their presence in the uterus and pelvic cavity. Symptoms of uterine fibroids include significant pelvic pain, abnormal uterine bleeding, reproductive dysfunction, miscarriages, early labor, and even infertility; and
WHEREAS, The pain, discomfort, stress, and other physical and emotional symptoms of living with uterine fibroids may significantly interfere with a womans quality of life, compromise her ability to function normally, work, or care for her family, and lead to more severe health and wellness issues; and
WHEREAS, Uterine fibroids are the most prevalent medical condition affecting women, with an estimated 30 percent of women developing a uterine fibroid by 35 years of age, and 80 percent of women developing a uterine fibroid by 50 years of age; and
WHEREAS, The exact number of affected women is unknown, as detection and diagnosis are difficult. Only one out of four women who have a uterine fibroid tumor exhibits symptoms severe enough to require treatment; and
WHEREAS, To properly diagnose uterine fibroids, access to health care is essential, as screening tests could include ultrasounds, magnetic resonance imaging, X-rays, and computerized tomography (CT) scans. Beyond diagnosis, surgery options include a myomectomy, which could potentially yield conception and full-term pregnancy complications, or a hysterectomy, which would make a woman unable to bear children. Invasive procedures like a myomectomy, however, are not recommended for women who want to conceive; and
WHEREAS, Fertility support, which is very common for women with uterine fibroids, is strongly contingent upon premium health care coverage. Lack of health care can strongly impact early detection, surgery options, and access to fertility support. Collectively, the side effects of uterine fibroids, invasive surgery options, and fertility issues considerably impact mental health and economic status due to missed work days and lost wages; and
WHEREAS, According to a study published in 2011, uterine fibroid tumors were estimated to cost the United States $5.9 billion to $34.4 billion annually with an estimated annual lost work cost of $1.6 billion to $17.2 billion through absenteeism and short-term disability in women between 25 and 54 years of age, inclusive; and
WHEREAS, The overall incidence of uterine fibroids is estimated to disproportionately and more severely impact African American and Hispanic women, resulting in an incidence rate that is three times greater in African American women and two times greater in Hispanic women compared to Caucasian women; and
WHEREAS, The differences in the incidence rates and the magnitude of the condition of uterine fibroids could be impacted by differences in access and use of health care services; and
WHEREAS, The State Department of Health Care Services and the State Department of Public Health, through a focus on womens health, encourage education and research on the condition to increase knowledge of uterine fibroids, improve methods of treatment, and develop an alternative to hysterectomies; and
WHEREAS, Observation of Uterine Fibroids Awareness Month in the month of July 2018 can assist in the aforementioned efforts, support and encourage women to engage in healthy dialogue, and promote a positive community; and
WHEREAS, Florida, Georgia, Maryland, New York, Pennsylvania, South Carolina, Virginia, Washington, D.C., and New Orleans, Louisiana, recognize Uterine Fibroids Awareness Month in July; and
WHEREAS, Public awareness and education campaigns on uterine fibroids prevention, screening, and symptoms are held during the month of July each year; and
WHEREAS, The San Diego Alumnae Chapter of Delta Sigma Theta Sorority, Inc., as part of its five-point programmatic thrust, conducted physical and mental health events in the City of San Diego, including a free Womens Health Forum on Uterine Fibroids. Its desire to expand awareness of the condition beyond the chapters region resulted in this statewide resolution; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby proclaims the month of July 2018 as Uterine Fibroids Awareness Month in California, recognizing the disparity in incidence rates among African American and Hispanic patients of uterine fibroids, and the need for greater research, treatment, and care options regarding uterine fibroids; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| Aug 30, 2018 | Chaptered by Secretary of State - Res. Chapter 176, Statutes of 2018. |
| Aug 30, 2018 | Enrolled and filed with the Secretary of State at 4:30 p.m. |
| Aug 24, 2018 | In Assembly. Ordered to Engrossing and Enrolling. |
| Aug 24, 2018 | Adopted and to Assembly. |
| Aug 21, 2018 | Ordered to special consent calendar. |
| Aug 8, 2018 | From committee: Ordered to third reading. |
| Jul 3, 2018 | Introduced measure version corrected. |
| Jul 3, 2018 | In Senate. To Com. on RLS. |
| Jul 2, 2018 | Coauthors revised. |
| Jun 21, 2018 | From committee: Be adopted. Ordered to Third Reading. (Ayes 9. Noes 0.) (June 21). |
| Jun 21, 2018 | Referred to Com. on RLS. |
| Jun 19, 2018 | From printer. |
| Jun 18, 2018 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 24, 2018 | Special Consent ACR257 | Senate Floor |
Passed |
|
| Jun 21, 2018 | Be adopted. To third reading. | Assembly Standing Committee on Rules |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | ACR 257 |
THIRD READING
Bill No: ACR 257
Introduced: 6/18/18
ASSEMBLY FLOOR: Read and adopted, 7/2/18
SUBJECT: Uterine Fibroids Awareness Month
DIGEST:
This resolution proclaims the month of July 2018 as Uterine Fibroids Awareness Month in California and recognizes the need for greater research, treatment, and care options regarding uterine fibroids.
ANALYSIS: This resolution makes the following legislative findings:
- Uterine fibroids are the most common noncancerous tumors that grow in the walls of the uterus in women of childbearing age, with no scientific confirmation of what causes the tumors.
- The pain, discomfort, stress, and other physical and emotional symptoms of living with uterine fibroids may significantly interfere with a woman's quality of life, compromise her ability to function normally, work, or care for her family, and lead to more severe health and wellness issues.
- Uterine fibroids are the most prevalent medical condition affecting women, with an estimated 30% of women developing a uterine fibroid by 35 years of age, and 80% of women developing a uterine fibroid by 50 years of age.
- The exact number of affected women is unknown, as detection and diagnosis are difficult. Only one out of four women who have a uterine fibroid tumor exhibits symptoms severe enough to require treatment; and, the overall incidence of uterine fibroids is estimated to disproportionately and more severely impact African American and Hispanic women resulting in an incidence rate that is three times greater in African American women and two times greater in Hispanic women compared to Caucasian women.
- According to a study published in 2011, uterine fibroid tumors were estimated to cost the United States $5.9 billion to $34.4 billion annually with an estimated annual lost work cost of $1.6 billion to $17.2 billion through absenteeism and short-term disability in women between 25 and 54 years of age.
- The State Department of Health Care Services and the State Department of Public Health, through a focus on women's health, encourage education and research on the condition to increase knowledge of uterine fibroids, improve methods of treatment, and develop an alternative to hysterectomies; and, public awareness and education campaigns on uterine fibroids prevention, screening, and symptoms are held during the month of July each year.
This resolution proclaims the month of July 2018 as Uterine Fibroids Awareness Month in California and recognizes the need for greater research, treatment, and care options regarding uterine fibroids.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
None received
None received
Prepared by: Jonas Austin / SFA / (916) 651-1520
8/8/18 16:10:45
**** END ****
ASSEMBLY THIRD READING
ATR Bill Id:ACR 257
Author:(Weber)
As Introduced Ver:
Majority vote
Committee | Votes | Ayes | Noes |
Rules | 9-0 | Cooley, Carrillo, Cervantes, Gallagher, Grayson, Mayes, Nazarian, Salas, Waldron |
SUMMARY: Proclaims the month of July 2018 as Uterine Fibroids Awareness Month in California and recognizes the need for greater research, treatment, and care options regarding uterine fibroids. Specifically, this resolution makes the following legislative findings:
- Uterine fibroids are the most common noncancerous tumors that grow in the walls of the uterus in women of childbearing age, with no scientific confirmation of what causes the tumors.
- The pain, discomfort, stress, and other physical and emotional symptoms of living with uterine fibroids may significantly interfere with a woman's quality of life, compromise her ability to function normally, work, or care for her family, and lead to more severe health and wellness issues.
- Uterine fibroids are the most prevalent medical condition affecting women, with an estimated 30% of women developing a uterine fibroid by 35 years of age, and 80% of women developing a uterine fibroid by 50 years of age.
- The exact number of affected women is unknown, as detection and diagnosis are difficult. Only one out of four women who have a uterine fibroid tumor exhibits symptoms severe enough to require treatment; and, the overall incidence of uterine fibroids is estimated to disproportionately and more severely impact African American and Hispanic women resulting in an incidence rate that is three times greater in African American women and two times greater in Hispanic women compared to Caucasian women.
- According to a study published in 2011, uterine fibroid tumors were estimated to cost the United States $5.9 billion to $34.4 billion annually with an estimated annual lost work cost of $1.6 billion to $17.2 billion through absenteeism and short-term disability in women between 25 and 54 years of age.
- The State Department of Health Care Services and the State Department of Public Health, through a focus on women's health, encourage education and research on the condition to increase knowledge of uterine fibroids, improve methods of treatment, and develop an alternative to hysterectomies; and, public awareness and education campaigns on uterine fibroids prevention, screening, and symptoms are held during the month of July each year.
FISCAL EFFECT: None
Analysis Prepared by: Michael Erke / RLS. / (916) 319-2800 FN: 0003583
Date of Hearing: June 21, 2018
ASSEMBLY COMMITTEE ON RULES
Ken Cooley, Chair
ABPCA Bill Id:ACR 257 (
Author:Weber) – As Introduced Ver:June 18, 2018
SUBJECT: Uterine Fibroids Awareness Month.
SUMMARY: Proclaims the month of July 2018 as Uterine Fibroids Awareness Month in California and recognizes the need for greater research, treatment, and care options regarding uterine fibroids. Specifically, this resolution makes the following legislative findings:
- Uterine fibroids are the most common noncancerous tumors that grow in the walls of the uterus in women of childbearing age, with no scientific confirmation of what causes the tumors.
- The pain, discomfort, stress, and other physical and emotional symptoms of living with uterine fibroids may significantly interfere with a woman’s quality of life, compromise her ability to function normally, work, or care for her family, and lead to more severe health and wellness issues.
- Uterine fibroids are the most prevalent medical condition affecting women, with an estimated 30 percent of women developing a uterine fibroid by 35 years of age, and 80 percent of women developing a uterine fibroid by 50 years of age.
- The exact number of affected women is unknown, as detection and diagnosis are difficult. Only one out of four women who have a uterine fibroid tumor exhibits symptoms severe enough to require treatment; and, the overall incidence of uterine fibroids is estimated to disproportionately and more severely impact African American and Hispanic women resulting in an incidence rate that is three time greater in African American women and two times greater in Hispanic women compared to Caucasian women.
- According to a study published in 2011, uterine fibroid tumors were estimated to cost the United States $5.9 billion to $34.4 billion annually with an estimated annual lost work cost of $1.6 billion to $17.2 billion through absenteeism and short-term disability in women between 25 and 54 years of age.
- The State Department of Health Care Services and the State Department of Public Health, through a focus on women’s health, encourage education and research on the condition to increase knowledge of uterine fibroids, improve methods of treatment, and develop an alternative to hysterectomies; and, public awareness and education campaigns on uterine fibroids prevention, screening, and symptoms are held during the month of July each year.
FISCAL EFFECT: None
REGISTERED SUPPORT / OPPOSITION:
Support
None on file
Opposition
None on file
Analysis Prepared by: Nicole Willis / RLS. / (916) 319-2800
Discussed in Hearing
View Older HearingsBill Author
Bill Co-Author(s):